King Hussein of Jordan and Non-Hodgkin Lymphoma: Understanding the Diagnosis

A name attached to a disease

King Hussein bin Talal of Jordan died in 1999, and his final illness has long been publicly linked to non-Hodgkin lymphoma and to treatment in the United States. Jordan's national cancer hospital carries his name, and the King Hussein Cancer Foundation states that it was founded in 2001 by royal decree.

We could not verify the specifics of his diagnosis or his care against a contemporaneous report we could check directly, so this page will not describe them.

The disease itself is worth the space, because "non-Hodgkin lymphoma" is not one illness. It is a label covering dozens of separate cancers with different speeds, different treatments, and very different outlooks.

What the lymph system is, and what goes wrong

Lymphocytes are white blood cells that fight infection, and they come in two kinds, B cells and T cells. They travel through lymph nodes, the spleen, the bone marrow, and a network of vessels.

Lymphoma is cancer of those cells. The National Cancer Institute splits it into Hodgkin lymphoma, which is defined by a specific abnormal cell, and non-Hodgkin lymphoma, which is everything else.

For 2026 the American Cancer Society projects 79,320 new cases of non-Hodgkin lymphoma and 19,970 deaths in the United States, the pair now shown on NCI's SEER Stat Facts page. NCI's PDQ summary has not caught up and still carries the older ACS estimate for 2025, 80,350 cases and 19,390 deaths, so the two NCI pages disagree as of August 2026. NCI's own measured incidence rate is 18.7 per 100,000 people per year. Men are affected more often than women, at 22.4 versus 15.6 per 100,000. The median age at diagnosis is 68.

The division that matters most

NCI sorts non-Hodgkin lymphoma into two prognostic groups, and the split is counterintuitive.

Indolent lymphoma grows slowly. NCI describes a median survival of around 20 years, and adds that in advanced stages it is typically not curable. Follicular lymphoma is the most common indolent type, making up about 20 percent of all non-Hodgkin lymphoma.

Aggressive lymphoma grows fast. It has a worse short-term outlook, and yet NCI states that "more than 70% of patients with aggressive NHL can be cured."

Read that pairing carefully. The slow cancer is usually controlled for years but not eliminated. The fast cancer is dangerous quickly and is often cured outright. Which group a patient is in changes the entire meaning of the word treatment, and it is the first thing to establish.

That is also why NCI's patient guidance lists "watchful waiting" among the treatment options. For some indolent lymphomas, starting drugs early has not been shown to help, so monitoring is the plan rather than the absence of one.

How it shows up

NCI lists swelling of lymph nodes in the neck, underarm, groin, or abdomen. It adds fever for no known reason, drenching night sweats, feeling very tired, and unexplained weight loss. Skin rash, itching, and unexplained pain in the chest, abdomen, or bones can also occur.

When fever, night sweats, and weight loss appear together, they are called B symptoms. NCI defines them precisely for lymphoma staging: "Unexplained weight loss (more than 10% of body weight in the 6 months before diagnosis). Unexplained fever with temperatures above 38°C. Drenching and recurrent night sweats."

That temperature is 100.4°F.

When to get checked

• A swollen lymph node that has not shrunk after four weeks, especially if it is painless and firm
• Any swollen node above the collarbone, at any size and any age
• Nodes swollen in more than one area of the body at once
• Fever above 100.4°F, recurring over weeks, with no infection to explain it
• Night sweats heavy enough to soak nightclothes or bedding
• Losing more than a tenth of your body weight in six months without trying
• Widespread itching with no rash, or unexplained pain in the abdomen or bones

Swollen nodes are usually infection. The ones that persist, spread, or arrive with fever and weight loss need a plan.

Getting the diagnosis right

The subtype determines everything, so the tissue has to be good enough to name it. NCI's clinician guidance warns that "outside biopsy specimens should be carefully reviewed by a hematopathologist," a pathologist who specializes in blood and lymph tissue.

NCI also compares biopsy methods, citing data from France where up to 40 percent of diagnoses were made by core needle biopsy and 60 percent by excisional biopsy, with excisional biopsy providing greater diagnostic certainty. Excisional means the entire node is removed.

The wider workup, per NCI, includes a complete blood count, blood chemistry, lactate dehydrogenase, hepatitis B and C and HIV testing, CT and PET scans, bone marrow aspiration and biopsy, and specialized staining and genetic analysis of the lymph node sample.

Staging uses the Lugano classification, which has replaced the older Ann Arbor system. NCI notes that PET-CT is useful for initial staging and follow-up, but that scans done partway through treatment do not carry reliable prognostic value in this disease.

Treatment, including transplant

NCI lists radiation therapy, chemotherapy, immunotherapy, targeted therapy, watchful waiting, surgery, and stem cell transplant among the options. Rituximab, an antibody that targets a marker on B cells, is a standard component of many regimens.

For disease that has come back, NCI states that "consolidation therapy for relapsed disease after reinduction therapy using autologous stem cell transplant (SCT) or allogeneic SCT can be considered."

A stem cell transplant is not a transplant of an organ. NCI explains that these procedures "restore blood stem cells in people who have had theirs destroyed by the high doses of chemotherapy or radiation therapy." An autologous transplant uses the patient's own cells. An allogeneic transplant uses a donor's cells, which adds an anti-cancer effect and also adds graft-versus-host disease, where donor immune cells attack the recipient's skin, liver, or intestines.

NCI is direct about the cost of that road. Conditioning chemotherapy runs a week or two. Long-term risks include infertility, cataracts, second cancers, and organ damage, and immune recovery takes several months to two years.

What the numbers show

SEER puts five-year relative survival for non-Hodgkin lymphoma at 74.3 percent overall, from cases diagnosed between 2016 and 2022. By stage, it lists 87.6 percent for stage I, 79.7 percent for stage II, 74.0 percent for stage III, and 63.6 percent for stage IV.

Notice how shallow that decline is. In many cancers, distant spread collapses the survival figure. In lymphoma, stage IV disease still carries a five-year figure above 60 percent, because these cancers respond to drugs that reach the whole body.

Incidence has been falling by about 0.6 percent a year, and death rates by about 2.4 percent a year. These are population trends and stage-level averages, and they describe groups rather than any one patient.

Sources

• https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq
• https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq
• https://www.cancer.gov/types/lymphoma/hp/adult-hodgkin-treatment-pdq
• https://www.cancer.gov/about-cancer/treatment/types/stem-cell-transplant
• https://seer.cancer.gov/statfacts/html/nhl.html
• https://www.cancer.org/research/cancer-facts-statistics.html
• https://www.khcc.jo/en/khcc